Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
ABL-105 by ABL Bio for Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer): Likelihood of Approval
ABL-105 is under clinical development by ABL Bio and currently in Phase II for Human Epidermal Growth Factor Receptor 2...
Data Insights
ABL-105 by ABL Bio for Gastroesophageal (GE) Junction Carcinomas: Likelihood of Approval
ABL-105 is under clinical development by ABL Bio and currently in Phase II for Gastroesophageal (GE) Junction Carcinomas. According to...